EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudie

Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study

Gustav Hjort iD, Christopher W Schwarz, Lars Erik Bryld, Kawa K Ajgeiy, Mads K Rasmussen, Trine Bertelsen, Kasper F Hjuler, Tomas N Dam, Nikolai Loft, Lone Skov iD

Clinical and Experimental Dermatology · 17.08.2026 · 51 (9) · 1621-1628

DOI: 10.1093/ced/llag142 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 25.03.2026. Verfasst von Gustav Hjort und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Adalimumab, Psoriasis. Die Arbeit nennt 22 Literaturangaben. Gefördert von: LEO Pharma, Novartis, Janssen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug survival of older biologic therapies is thought to be influenced by the availability of newer biologic therapies and lower-cost biosimilars. However, there are limited data examining changes in drug survival over time.

Objectives

To examine the drug survival of adalimumab over the past two decades.

Methods

This observational, retrospective, multicentre cohort study analysed data from patients with moderate-to-severe psoriasis treated with adalimumab registered in the Danish nationwide registry, DERMBIO. Patients were stratified into two distinct time periods based on initiation date: an early period (2007–2016) and a late period (2019–2024). Kaplan–Meier curves were used to present unadjusted drug survival curves. A multivariable adjusted Cox proportional hazards model was used to compare the risk of drug discontinuation between the two periods.

Results

In total, 2336 patients were included: 861 in the early period and 1475 in the late period. We found a significantly lower risk of drug discontinuation in the late period compared with the early period (adjusted hazard ratio 0.78, 95% confidence interval 0.68–0.90, P < 0.001), despite the concurrent availability of newer and more effective biologic therapies.

Conclusions

This study found that the increased number of available biologic therapies did not have a negative impact on the drug survival of adalimumab. On the contrary, discontinuation risk was significantly lower in 2019–2024 compared with 2007–2016. The concurrent introduction of lower-cost biosimilars and the associated rise in dose escalation may have contributed to the improved drug survival observed in the later period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabPsoriasisHumansFemaleRetrospective StudiesDenmarkMaleMiddle AgedRegistriesAdultKaplan-Meier EstimateBiosimilar PharmaceuticalsProportional Hazards ModelsTime Factors

Substanzen

AdalimumabBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark.
  • Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Dermatology, Odense University Hospital, Odense, Denmark.
  • Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Gustav Hjort, Lone Skov

Förderung

  • LEO Pharma
  • Novartis
  • Janssen

Zitieren

APA

Hjort, G., Schwarz, C. W., Bryld, L. E., Ajgeiy, K. K., Rasmussen, M. K., Bertelsen, T., Hjuler, K. F., Dam, T. N., Loft, N., & Skov, L. (2026). Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study. Clinical and Experimental Dermatology, 51(9), 1621-1628. https://doi.org/10.1093/ced/llag142

Vancouver

Hjort G, Schwarz CW, Bryld LE, Ajgeiy KK, Rasmussen MK, Bertelsen T, et al. Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study. Clinical and Experimental Dermatology. 2026;51(9):1621-1628. doi:10.1093/ced/llag142

BibTeX
@article{Hjort2026,
  author = {Hjort, Gustav and Schwarz, Christopher W and Bryld, Lars Erik and Ajgeiy, Kawa K and Rasmussen, Mads K and Bertelsen, Trine and Hjuler, Kasper F and Dam, Tomas N and Loft, Nikolai and Skov, Lone},
  title = {Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {9},
  pages = {1621--1628},
  doi = {10.1093/ced/llag142}
}
Kostenlos starten →